• Discover

      the potential of targeted therapeutics

    • Innovate

      at the edge of cancer research

    • Target

      the right drugs to the right cells

    • Hope

      for patients, families & friends

Targeting therapeutics to cancer cells



Dr Keith Powell

Chairman

Keith has been in biotechnology since it started. Having worked for GSK and ICI/Zeneca in genetics/molecular biology he led several large groups including discovery and finally running the patent group. He then worked at Maxygen on the West Coast leading the small molecule group through the IPO and growing a business that eventually spun out as ‘Codexis’. On returning to the UK, Keith joined the Bloomsbury BioSeed Fund and Longbow Capital and acted as CEO for several portfolio companies. He led Domainex through a merger with NCE to form a successful business in protein structure-based chemistry and Polytherics was built through organic growth since 2005 to a company of >80 people. Keith is currently chairman of Domainex and Canbex and has a range of other Board interests in the healthcare industry.



Dr Davidson Ateh

CEO

Davidson is an entrepreneur operating in the life sciences. He has an interdisciplinary scientific background in bioengineering and was a past recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship. Davidson has significant technology translation experience including proof-of-concept studies, IP protection, non-dilutive grant applications, partnering, licensing and raising investment. He has won awards for his scientific and commercial activities. Davidson is a co-inventor of the Oncojan™ drug delivery platform, co-founder of BioMoti and leads product and business development activities.



Prof Joanne Martin

Advisor

Jo is the NHS National Clinical Director of Pathology, Director of Academic Health Sciences (and Consultant Histopathologist) at Barts Health NHS Trust and Professor of Pathology at Queen Mary, University of London. Jo has an international reputation in the study of diseases with over 115 publications including high impact journals such as Science and Nature. She is an experienced business leader (MA in Leadership) with a track record of running a large NHS Trust Division (£89 million budget per annum), delivering and commissioning a £40 million building, and 2 major IT system implementations (both over £1.3 million). She has an excellent understanding of technology transfer previously been an assessor of early stage technologies for Nikko Principal Investments Ltd. Jo is a co-inventor of the Oncojan™ drug delivery platform, co-founder of BioMoti and acts as an advisor.